Assertio Holdings | DEPO - Operating Expenses


Assertio Holdings reported $105.8M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Assertio Holdings USD 105.8M 12.5M Sep/2025
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
Cara Therapeutics USD 5.94M 983K Sep/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 17.44B 1.53B Mar/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Merck USD 18.17B 8.01B Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Pfizer USD 90.1B 77.19B Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026